Publicaciones en las que colabora con Ruth Vera García (13)

2024

  1. Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 869-879

  2. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. CAR-T Cells for the Treatment of Lung Cancer

    Life, Vol. 12, Núm. 4

  2. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  3. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  4. Cutting-Edge CAR Engineering: Beyond T Cells

    Biomedicines, Vol. 10, Núm. 12

  5. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

    Cells, Vol. 11, Núm. 15

  6. Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

    Cancers, Vol. 14, Núm. 18

  7. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

2021

  1. Hyperprogressive disease: Main features and key controversies

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  2. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1